EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma

Naoki Uchihara, Nobuharu Tamaki, Hiroyuki Marusawa, Naohito Urawa, Chitomi Hasebe, Hirotaka Arai, Hironori Ochi, Masahiko Kondo, Nami Mori, Keiji Tsuji, Hideki Fujii, Chikara Ogawa und 18 weitere

Anticancer Research · 2026-08 · 46 (8) · 4443-4452

DOI: 10.21873/anticanres.18300 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Naoki Uchihara und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Liver Neoplasms.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsPhenylurea CompoundsQuinolinesAgedFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedTreatment Outcome

Stichwörter der Autor:innen

Hepatocellular carcinomadurvalumablenvatinibsequential therapytremelimumab

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorslenvatinibPhenylurea CompoundsQuinolinestremelimumab

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Ise Hospital, Ise, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Asahikawa Hospital, Asahikawa, Japan.
  • Department of Gastroenterology and Hepatology, Japanese Red Cross Maebashi Hospital, Maebashi, Japan.
  • Center for Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Ehime, Japan.

Zitieren

APA

Uchihara, N., Tamaki, N., Marusawa, H., Urawa, N., Hasebe, C., Arai, H., Ochi, H., Kondo, M., Mori, N., Tsuji, K., Fujii, H., Ogawa, C., Uchida, Y., Mori, H., Toshimori, J., Okamoto, E., Shigeno, M., Akahane, T., Narita, R., …, & Japanese Red Cross Liver Study Group (2026). Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer Research, 46(8), 4443-4452. https://doi.org/10.21873/anticanres.18300

Vancouver

Uchihara N, Tamaki N, Marusawa H, Urawa N, Hasebe C, Arai H, et al. Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Anticancer Research. 2026;46(8):4443-4452. doi:10.21873/anticanres.18300

BibTeX
@article{Uchihara2026,
  author = {Uchihara, Naoki and Tamaki, Nobuharu and Marusawa, Hiroyuki and Urawa, Naohito and Hasebe, Chitomi and Arai, Hirotaka and Ochi, Hironori and Kondo, Masahiko and Mori, Nami and Tsuji, Keiji and Fujii, Hideki and Ogawa, Chikara and Uchida, Yasushi and Mori, Hiromitsu and Toshimori, Junichi and Okamoto, Eisuke and Shigeno, Masaya and Akahane, Takehiro and Narita, Ryoichi and Yoshida, Hideo and Yokohama, Keisuke and Kubotsu, Yoshihito and Yasuda, Yoichi and Tada, Toshifumi and Nakamura, Shinichiro and Tsuchiya, Kaoru and Yasui, Yutaka and Izumi, Namiki and Kurosaki, Masayuki and Japanese Red Cross Liver Study Group, Japanese Red Cross Liver Study Group},
  title = {Efficacy of Lenvatinib as Subsequent Therapy After Combination Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma},
  journal = {Anticancer Research},
  year = {2026},
  volume = {46},
  number = {8},
  pages = {4443--4452},
  doi = {10.21873/anticanres.18300}
}
Kostenlos starten →